May 16, 2016 10:29am


P2 Eclipse trial fails to meet improvement in overall patient survival


Pre-market trading halted with ADRO DOWN more than 25%


Calling it an “unexpected outcome”, ADRO said its P2 Eclipse study in patients with pancreatic cancer patients who failed at least two prior therapies showed a divergence of data from the results of its P2a study.

Median overall survival (MOS) in the third-line and greater setting was 3.8 months for patients treated with the immunotherapy regimen of CRS-207 and GVAX Pancreas, 5.4 months for patients treated withCRS-207 alone and 4.6 months for patients administered chemotherapy.


The Bottom Line:  ADRO’s findings are disappointing to say the least. 

ADRO closed UP Friday $0.45 to $10.69 and is DOWN -$2.78 or -26% to $7.91 in Monday's morning session.